Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Health Catalyst, Inc.
HCAT
NASDAQ·Healthcare·Medical - Healthcare Information Services·Mkt cap $153.0M
$2.08
▲ +0.48%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$0.96 - $4.13
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 49.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Purpose-built healthcare data platform with deep clinical and operational expertise
- Integrated AI and machine learning capabilities that enhance analytics accuracy and actionability
- National data ecosystem providing benchmarking, collaboration, and thought leadership advantages
- Comprehensive solution suite addressing multiple healthcare pain points across the care continuum
- Established customer base with high switching costs and expanding use cases
Bear Case
2 risks
- Above-average volatility (beta 1.7).
- High premium - requires strong execution
Growth
Turning profitable
Increasing healthcare industry demand for data-driven decision making and digital transformation
Value
High premium - requires strong execution
Momentum
Hot
+76.9% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying HCAT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 5, 2026
MAY 11, 2026
Reported EPS of $0.02 vs $0.01 consensus (+100.0% surprise). Revenue of $70.8M vs $69.2M expected (+2.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+100.0%
Next: May 5, 2026
Revenue trend · last 8Q
—
—
+6%
+6%
+6%
-0%
-6%
-11%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$75.9M
$76.4M
$79.6M
$79.4M
$80.7M
$76.3M
$74.7M
$70.8M
Margins · last 8Q
Gross
—
Operating
—
Profit
-156.9%
Wall Street consensus
6 analysts · 17% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
17%
Hold
83%
Sell
0%
Median Price Target
$1.75
▼ -15.9% vs $2.08
Latest: Stephens · $1.75 · May 12, 2026
1 analyst covering